IGC Pharma, Inc.: Form 10-Q for the period ended Jun 30, 2016
Filed with the SEC on Aug 16, 2016 and accepted by EDGAR at Aug 16, 2016, 16:22 ET.
Management's discussion and analysis
As filed, 16,248 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q, and the Annual Report on Form 10-K filed with the SEC on July 14, 2016. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in our Annual Report on Form 10-K filed with the SEC on July 14, 2016, including the risk factors set out in Item 1A therein. Therefore, the financial statements included in this Report should be read in conjunction with the audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on July 14, 2016.
Company Overview
India Globalization Capital, Inc. (“IGC”), a Maryland corporation, was organized on April 29, 2005 as a blank check company formed for the purpose of acquiring one or more businesses with operations primarily in India, and now Malaysia, Hong Kong and China, through a merger, capital stock exchange, asset acquisition or other similar business combination or acquisition. On March 8, 2006, the Company completed an initial public offering. IGC is headquartered in the United States. The operations of IGC are based in USA, Hong Kong, India, and Malaysia. In the United States, throughout our research on phytocannabinoid-based therapies, we develop intellectual property for the treatment of life altering or life threatening conditions; for the purpose of leasing, we also build state-of-the art farming facilities. In India, Hong Kong and China, we lease equipment, trade commodities and electronic components, and in Malaysia we develop manage and sell residential and commercial real estate.
Phytocannabinoids are chemical compounds that exert a range of effects on the human body, including impacting the immune response, gastrointestinal maintenance and motility, muscle functioning, and nervous system response and functioning. We have filed five provisional patents with the United States Patent and Trademark Office (“USPTO”), in the combination therapy space, for the indications of pain, medical refractory epilepsy and cachexia as part of our intellectual property strategy focused on the phytocannabinoid based health care industry. There is no guarantee that filing a provisional or a non-provisional patent application will result in a successful registration with the USPTO. In addition, when federal laws become more favorable, we intend to build leading edge facilities that we can use to grow, extract, and supply pharmaceutical grade phytocannabinoids.
In Hong Kong, through a majority owned subsidiary, we operate a trading business. Most of our revenue comes from this business. However, for some time, we have been in the process of pivoting away from this business, as there has been a macroeconomic slow-down in this sector, to higher margin niche businesses such as indoor farming, specialized construction and specialty leasing, by organically developing or acquiring this expertise.
Our short-term plans are to develop, test, and patent phytocannabinoid based pharmaceutical therapies, build leading edge facilities that can be used to grow and extract pharmaceutical grade phytocannabinoids and develop the hotel complex in Genting Malaysia, while jettisoning our trading business. Our medium-term plans are to acquire companies or management that can help us advance our bio-pharmaceutical and our technology businesses. Our long-term plan is to establish, in the USA, IGC as a leading provider of phytocannabinoid based pharmaceutical and nutraceutical products.
Subsidiaries Overview
Incorporated on February 19, 2007, India Globalization Capital Mauritius Limited (IGC-M) is a Mauritius based company that manages and beneficially owns all the subsidiaries based in India that were purchased in 2009: IGC Materials Private Limited (“IGC-MPL”), IGC Logistics Private Limited (“IGC-LPL”), IGC India Mining and Trading Private Limited (“IGC-IMT”) and Techni Bharathi Private Limited (“TBL”). TBL was incorporated on June 19, 1982, in Cochin, India. TBL is an engineering and construction company currently focused on the heavy equipment leasing business. TBL has a focus in the Indian states of Kerala, Karnataka, and Tamil Nadu. On March 31, 2013, TBL became a fully-owned subsidiary of IGC. The other Indian subsidiaries are focused on the trading of materials such as iron ore to customers in India and China.
HK Ironman is a Hong Kong-based company incorporated on December 20, 2010 to acquire PRC Ironman. PRC Ironman was incorporated as Linxi Hefei Economic & Trade Co., Ltd. in China on January 8, 2008. HK Ironman owns 95% of PRC Ironman. PRC Ironman is engaged in the processing of iron ore from sand and dirt at its beneficiation plants in southwest Linxi in the autonomous region of eastern Inner Mongolia. On February 2, 2015, IGC filed a lawsuit for the cancellation of shares that were issued to the shareholders of HK Ironman. The lawsuit is in the preliminary stages and is expected to settle by fiscal year 2017.
IGC HK Mining and Trading Limited (“IGC-HK”) is a Hong Kong-based company incorporated in January 2013. In September 2014, we changed the subsidiary’s name to IGC Cleantech (“IGC-CT”). IGC-CT is a wholly-owned subsidiary of IGC-Mauritius and is not currently an operational subsidiary.
Golden Gate Electronics Limited (“Golden Gate”), a corporation organized and existing under the laws of Hong Kong and now known as IGC International Limited (“IGC-INT”), operates an e-commerce platform for trading of commodities and electronic components. In May 2014, IGC completed the acquisition of 51% of Golden Gate issued and outstanding share capital of. As we are curtailing our low margin trading activity and realigning resources to the phytocannabinoid industry and real estate development and international project management industry, we are negotiating an exit from our ownership of Golden Gate. We anticipate exiting this acquisition and eventually the trading business.
In June 2014, we entered into an agreement with TerraSphere Systems LLC to develop multiple facilities to produce organic leafy green vegetables utilizing TerraSphere’s advanced pesticide-free organic indoor farming technology. Under the agreement, we will own 51% of each venture once production is operational, and will have a right of first refusal to participate in all future build-outs. Additionally, in consideration for our issuance of 50,000 shares of common stock, we received a seven-year option to purchase TerraSphere Systems for cash or additional shares of our common stock. We are negotiating a conversion of the investment into shares of a Canadian public vehicle that TerraSphere expects to merge into.
In December 2014, we entered into a Purchase Agreement with Apogee Financial Investments, Inc. (“Apogee”), the previous sole owner of the outstanding membership interests of Midtown Partners & Co., LLC, a Florida limited liability company registered as a broker-dealer under the Securities Exchange Act of 1934 (“Midtown Partners”), to acquire 24.9% of the outstanding membership interests in Midtown Partners. In consideration of the initial membership interests, we issued to Apogee 1,200,000 shares of our common stock. As a result of Apogee’s inability to obtain requisite approvals to sell us their remaining interest in Midtown Partners, we will remain a 24.9% owner in Midtown Partners for the foreseeable future. We are not seeking to consummate the acquisition of the remaining interest in Midtown Partners at this time.
In February 2016, we completed the acquisition of 100% of the outstanding share capital of Cabaran Ultima Sdn. Bhd., a corporation organized and existing under the laws of Malaysia (“Ultima”), from RGF Land Sdn. Bhd. (“Land”), the sole shareholder of Ultima. Ultima holds 51% of RGF Cabaran Sdn. Bhd., which holds 75% of RGF Construction Sdn. Bhd. Ultima and its management’s expertise include the following: (i) building agro-infrastructure for growing medicinal plants and botanical extraction, and (ii) construction of high-end luxury complexes such as service apartments, luxury condominiums and hotels.
Results of Operations
Three Months ended June 30, 2016 Compared to Three Months ended June 30, 2015
Revenue - Total revenue was $288,493 for the three months ended June 30, 2016 as compared to $1,858,809 for the three months ended June 30, 2015. In the three-month periods ended June 30, 2016 and 2015, the revenue was deliberate and primarily generated by the trading of electronics and rental of heavy equipment. The decrease in revenue is primarily from a decrease in the volume of the electronic trading business, which we are in the process of curtailing.
Cost of Revenue (excluding depreciation) – Cost of revenue for the three months ended June 30, 2016 was $201,854 as compared to $1,654,769 for the three months ended June 30, 2015. The decrease in cost of revenue stems from a decrease in the volume of business as reflected in the decrease in revenue.
Selling, General and Administrative - Selling, general and administrative expenses were $307,772 for the three months ended June 30, 2016 as compared to $305,403 for the three months ended June 30, 2015. Most of the expenses are public-company related expenses.
Depreciation – The depreciation expense was approximately $97,672 in the three months ended June 30, 2016 as compared to $155,974 in the three months ended June 30, 2015.
Interest and other financial expenses – The interest expense and other financial expenses for the three months ended June 30, 2016 were approximately $43,278 as compared to approximately $61,914 for the three months ended June 30, 2015. Most of the interest is paid with shares of the Company and is therefore non-cash.
Other income/(loss) – Other income was $1,755 for the three-month period ended June 30, 2016 as compared to other income/(loss) of $(35,057) in June 30, 2015. Other income for June 30, 2016 includes the rent of apartment owned by one of the subsidiaries and the income by supply of skilled operators for the heavy equipment rental business.
Consolidated Net Income/(loss) – In the three months ended June 30, 2016, the Company reported a GAAP net income loss of $383,566 and a GAAP EPS loss of $0.02 compared to a GAAP net income loss of $382,699 and a GAAP EPS loss of $0.03 for the three months ended June 30, 2015. The lower loss in the first quarter of fiscal 2016 is attributable to lower selling, general and administrative expenses.
Off-Balance Sheet Arrangements
We do not have any undisclosed investments in special purpose entities or undisclosed borrowings or debt.
Liquidity and Capital Resources
This liquidity and capital resources discussion compares the consolidated company financial position for the three-month periods ended June 30, 2016 and 2015.
During the three months ended June 30, 2016, cash provided in operating activities was $202,908 compared to $548,446 used during the three months ended June 30, 2015.
During the three months ended June 30, 2016, $117,812 cash was used in investing activities from continuing operations as compared to $26,396 used during the same period in 2015.
For the quarter ended June 30, 2016, our non-GAAP cash burn was approximately $254,654 after adjusting for $97,672 of depreciation and $31,240 of non-cash interest.
At the end of June 30, 2016, our cash and cash equivalents along with restricted cash was $1,325,550 and working capital of $107,596. We currently have sufficient cash to continue business operations with limited expansion.
Critical Accounting Policies
See Note 2 - Significant Accounting Policies of the Notes to Consolidated Financial Statements in Part I, Item 1 of this report for a discussion of our critical accounting policies.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. This report and the documents incorporated in this report by reference contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Additionally, we or our representatives may, from time to time, make other written or verbal forward-looking statements. In this report and the documents incorporated by reference, we discuss plans, expectations and objectives regarding our business, financial condition and results of operations. Without limiting the foregoing, statements that are in the future tense, and all statements accompanied by terms such as “believe,” “project,” “expect,” “trend,” “estimate,” “forecast,” “assume,” “intend,” “plan,” “target,” “anticipate,” “outlook,” “preliminary,” “will likely result,” “will continue” and variations of them and similar terms are intended to be “forward-looking statements” as defined by federal securities laws. We caution you not to place undue reliance on forward-looking statements, which are based upon assumptions, expectations, plans and projections. Forward-looking statements are subject to risks and uncertainties, including those identified in the “Risk Factors” included in this report and in the documents incorporated by reference that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date when they are made. Except as required by federal securities law, we do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations or the occurrence of unanticipated events after the date of those statements. We intend that all forward-looking statements made will be subject to safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act and Section 21E of the Exchange Act.
Forward-looking statements are based upon, among other things, our assumptions with respect to:
- our ability to successfully register patents, market new products and services, including but not limited to real estate in Malaysia, leasing products in India, Malaysia and the USA, and achieve customer acceptance in the industries we serve;
- our ability to accurately predict the future demand of our products;
- competition in exploiting phytocannabinoids for pharmaceutical and nutraceutical applications;
- federal and state legislation and administrative policy for regulating phytocannabinoids;
- our ability (based in part on regulatory concerns) to build and or lease facilities for vertical farming that can eventually be used by us to produce pharmaceutical grade phytocannabinoids;
- our ability to obtain and protect patents for the use of phytocannabinoids;
- our ability to enter into new licenses and contracts, and perform them successfully;
- current and future economic and political conditions, in specifically but not limited to North America, Malaysia, India, and China; and
- other assumptions described in this prospectus supplement underlying or relating to any forward-looking statements.
You should consider the limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements. As noted above, these forward-looking statements speak only as of the date when they are made. Moreover, in the future, we may make forward-looking statements through our senior management that involve the risk factors and other matters described in this report, as well as other risk factors subsequently identified, including, among others, those identified in our filings with the SEC in our quarterly reports on Form 10-Q and our current reports on Form 8-K.
Market risk
As filed, 159 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Pursuant to Item 305(e) of Regulation S-K, the Company is not required to provide the information required by this Item as it is a “smaller reporting company.”
Controls and procedures
As filed, 1,770 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, management conducted an evaluation, under the supervision and with the participation of its Chief Executive Officer (CEO) and its principal financial and accounting officer (PFAO), of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Securities Exchange Act of 1934. Based upon that evaluation, our CEO and PFAO concluded that our disclosure controls and procedures are effective.
Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act as controls and other procedures that are designed to ensure that information required to be disclosed by us in reports filed with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed under the Exchange Act is accumulated and communicated to our management, including our CEO and PFAO, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There were no changes in our internal controls over financial reporting during our fiscal quarter ended June 30, 2016 which were identified in conjunction with Management’s evaluation required by paragraph (d) of Rule 13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
Risk factors
As filed, 179 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have not been any material changes with regard to the risk factors previously disclosed in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2016.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-04-01 to 2016-06-30 | $288.5k | us-gaap:Revenues |
| Cost of revenue | 3 months2016-04-01 to 2016-06-30 | $201.9k | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months2016-04-01 to 2016-06-30 | $307.8k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2016-04-01 to 2016-06-30 | −$318.8k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2016-04-01 to 2016-06-30 | $43.3k | us-gaap:InterestExpense |
| Income tax | 3 months2016-04-01 to 2016-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-04-01 to 2016-06-30 | −$383.6k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-04-01 to 2016-06-30 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-04-01 to 2016-06-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-04-01 to 2016-06-30 | 23,312,056 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2016-04-01 to 2016-06-30 | $202.9k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2016-04-01 to 2016-06-30 | $3.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-06-30 | $1.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-06-30 | $3.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-06-30 | $18.5m | us-gaap:Assets |
| Current liabilities | At period end2016-06-30 | $3.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-06-30 | $4.9m | us-gaap:Liabilities |
| Long-term debt | At period end2016-06-30 | $596.3k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2016-06-30 | $12.6k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2016-06-30 | $13.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001185185-16-005260. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.